Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Junji Health Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China for its independently developed in vivo biological therapy product, LBP-ShC4, to conduct clinical trials in China. The product is intended for the treatment of androgenetic alopecia (AGA). Previously, clinical trials for the same indication were approved by the U.S. Food and Drug Administration (FDA) in May 2025. According to the announcement, as of February 2026, Fosun Pharmaceutical Group's cumulative R&D investment in LBP-ShC4 was approximately RMB 20 million. Currently, there are no in vivo biological therapy products (including monotherapy or combination therapy) approved for the treatment of androgenetic alopecia globally. Fosun Pharmaceutical stated that LBP-ShC4 still needs to complete a series of clinical studies in China and obtain approval from the NMPA before it can be marketed. The company also cautioned that there is a risk that clinical trials may be terminated due to safety and/or efficacy issues.

https://finance.sina.com.cn/roll/2026-03-17/doc-inhrfshe9652393.shtml